pubmed-article:17129359 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0599757 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0036847 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C1155873 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:17129359 | lifeskim:mentions | umls-concept:C0911646 | lld:lifeskim |
pubmed-article:17129359 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:17129359 | pubmed:dateCreated | 2007-4-10 | lld:pubmed |
pubmed-article:17129359 | pubmed:abstractText | We demonstrated here for the first time that zerumbone (ZER), a natural cyclic sesquiterpene, significantly suppressed the proliferation of promyelocytic leukemia NB4 cells among several leukemia cell lines, but not human umbilical vein endothelial cells (HUVECs), by inducing G2/M cell cycle arrest followed by apoptosis with 10 microM of IC50. Treatment of NB4 cells with growth-suppressive concentrations of ZER resulted in G2/M cell cycle arrest that was associated with a decline of Cyclin B1 protein, but with the phosphorylation of ATM/ Chk1/Chk2. In addition, ZER induced the phosphorylation of Cdc25C at the Thr48 residue and Cdc2 at the Thr14/Tyr15 residues. Furthermore, ZER-induced apoptosis in NB4 cells was initiated by the expression of Fas (CD95)/Fas Ligand (CD95L), concomitant with the activation of caspase-8. ZER was also found to induce the cleavage of Bid, a mediator that is known to connect the Fas/CD95 cell death receptor to the mitochondrial apoptosis pathway. ZER also induced the cleavage of Bax and Mcl-1 proteins, but not Bcl-2 or Bcl-XL. ZER-induced apoptosis took place in association with a loss of the mitochondrial transmembrane potential as well as the activation of caspase-3 and -9, resulting in the degradation of the proteolytic poly (ADP-ribose) polymerase (PARP). ZER also triggered a release of cytochrome c into the cytoplasm. Both antagonistic anti-Fas antibody ZB4 and pan-caspase inhibitor Z-VAD inhibited ZER-induced apoptosis in NB4 cells. Taken together, ZER is an inducer of apoptosis in leukemic cells that specifically triggers the Fas/CD95- and mitochondria-mediated apoptotic signaling pathway. | lld:pubmed |
pubmed-article:17129359 | pubmed:language | eng | lld:pubmed |
pubmed-article:17129359 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17129359 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17129359 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17129359 | pubmed:month | Jan | lld:pubmed |
pubmed-article:17129359 | pubmed:issn | 1347-9032 | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:OhigashiHajim... | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:IkedaYasuoY | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:KizakiMasahir... | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:YamatoKenjiK | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:MurakamiAkira... | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:NakazatoTomon... | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:ItoKeisukeK | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:ShimizuTakats... | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:ChenChien-Kan... | lld:pubmed |
pubmed-article:17129359 | pubmed:author | pubmed-author:XianMingjiM | lld:pubmed |
pubmed-article:17129359 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17129359 | pubmed:volume | 98 | lld:pubmed |
pubmed-article:17129359 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17129359 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17129359 | pubmed:pagination | 118-26 | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:meshHeading | pubmed-meshheading:17129359... | lld:pubmed |
pubmed-article:17129359 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17129359 | pubmed:articleTitle | Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway. | lld:pubmed |
pubmed-article:17129359 | pubmed:affiliation | Department of Internal Medicine, Division of Hematology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku Tokyo, 160-8582 Japan. | lld:pubmed |
pubmed-article:17129359 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17129359 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17129359 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17129359 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17129359 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17129359 | lld:pubmed |